These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35063943)

  • 1. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group.
    Vergote I; Van Nieuwenhuysen E; De Waele S; Vulsteke C; Lamot C; Van den Bulck H; Claes N; Graas MP; Debrock G; Spoormans I; Vuylsteke P; Honhon B; Verhoeven D; De Maeseneer D; Dirix L; Mebis J; Vroman P; Denys H; Martinez Mena C; Pelgrims G; Van Steenberghe M; van Gorp T; Gennigens C
    Int J Gynecol Cancer; 2022 Jun; 32(6):753-760. PubMed ID: 35063943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
    Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
    Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
    Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
    Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
    Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
    Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
    Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    Moore KN; Bookman M; Sehouli J; Miller A; Anderson C; Scambia G; Myers T; Taskiran C; Robison K; Mäenpää J; Willmott L; Colombo N; Thomes-Pepin J; Liontos M; Gold MA; Garcia Y; Sharma SK; Darus CJ; Aghajanian C; Okamoto A; Wu X; Safin R; Wu F; Molinero L; Maiya V; Khor VK; Lin YG; Pignata S
    J Clin Oncol; 2021 Jun; 39(17):1842-1855. PubMed ID: 33891472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
    Falandry C; Rousseau F; Mouret-Reynier MA; Tinquaut F; Lorusso D; Herrstedt J; Savoye AM; Stefani L; Bourbouloux E; Sverdlin R; D'Hondt V; Lortholary A; Brachet PE; Zannetti A; Malaurie E; Venat-Bouvet L; Trédan O; Mourey L; Pujade-Lauraine E; Freyer G;
    JAMA Oncol; 2021 Jun; 7(6):853-861. PubMed ID: 33885718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
    Zhang L; Zhou Q
    Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
    J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
    Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.
    Hall M; Bertelli G; Li L; Green C; Chan S; Yeoh CC; Hasan J; Jones R; Ograbek A; Perren TJ
    Int J Gynecol Cancer; 2020 Feb; 30(2):213-220. PubMed ID: 31780570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
    Stark D; Nankivell M; Pujade-Lauraine E; Kristensen G; Elit L; Stockler M; Hilpert F; Cervantes A; Brown J; Lanceley A; Velikova G; Sabate E; Pfisterer J; Carey MS; Beale P; Qian W; Swart AM; Oza A; Perren T
    Lancet Oncol; 2013 Mar; 14(3):236-43. PubMed ID: 23333117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.